UBS maintains Buy on Veracyte; price target raised to $65
UBS maintains a Buy rating on Veracyte and raises its price target to $65.00 per share from $52.00, per Benzinga via TradingView News.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.